DanCann Pharma
DanCann Pharma · page 2
- Markets & Stocks
OCT Secures MHRA Approval For Clinical Trials, Cantourage Posts First Profits, & More From DanCann Pharma
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”OCTP.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] The London Stock Exchange listed pharmaceutical cannabis company announced yesterday that it has at last secured MHRA approval for its Phase 1 Clinical Trials for its lead compound.
- Markets & Stocks
European Cannabis Stocks Review: Akanda Implement’s 1-10 Stock Consolidation, IMC Slashes 20% Of Staff, & More From DanCann Pharma
Akanda Akanda has become the latest NASDAQ-listed cannabis company to enact a stock consolidation in order to avoid delisting from the stock exchange.
- Adult-Use
European Cannabis Stocks Review: SynBiotic Jumps On German Progress, DanCann Pharma Recovers & More From Cannabis Poland
SynBiotic Earlier this week the German Health Minister Karl Lauterbach officially unveiled his plans for the legalisation of adult-use cannabis, a week after some details were leaked to the press.
- Adult-Use
European Cannabis Stocks Review: SEED Loses Recent Gains As Stock Drops 30%, DanCann Performs Well Despite Lower Estimates, & More From DeepVerge
THIS week saw news emerge that countries across the globe were making significant moves towards the liberalisation of cannabis regulation, with Spain, Japan and Ukraine all exploring the legalisation of medical cannabis.
- Markets & Stocks
European Cannabis Stocks Roundup: Aurora Stocks Jump On EU Medical Market Growth Despite $1bn Loss
IT’S been a jam-packed week for the global cannabis industry as a host of companies including Aurora, Halo Collective, Dancann Pharma, Yooma Wellness and Intercure, among others, reported quarterly results.
